Thus, for example, endocrine therapy is standard for patients with luminal tumors expressing estrogen and progesterone receptors [30], while HER-2 positive breast cancer patients might be treated with drugs targeting specifically HER-2 [31]. This evidence concerns the gene ERBB2 and breast carcinoma.